Keywords
atypical squamous cells of the cervix of the uterus
uterine cervicitis
bacterial vaginosis
human papillomavirus (HPV)
How to Cite
Abstract
Introduction: During October and December 2024, cervical cytology screening campaigns were conducted in the municipalities of San Pedro Perulapán and Cuscatancingo, both located in the metropolitan area of San Salvador, El Salvador. Objective: To detect human papillomavirus (HPV) infection and cervical abnormalities. Methodology: This was a descriptive, cross-sectional study involving cytological and molecular analyses of cervical samples collected via the Papanicolaou (Pap smear) technique. Population: The study included 87 women aged between 21 and 76 years who provided informed consent and underwent both cervical cytology and molecular testing for HPV. Results: Cervical cytology results indicated that 96.15% of participants tested negative for intraepithelial lesions, while 3.85% presented with low-grade squamous intraepithelial lesions (LSIL). Additionally, mild to severe inflammation was observed in 11.54% of cases, and cytological features suggestive of bacterial vaginosis were identified in 7.69% of participants Molecular HPV screening revealed a 9.84% positivity rate for high-risk HPV. Conclusion: Cytological analysis revealed a low prevalence of abnormal findings, which were mainly associated with infections or benign and treatable conditions rather than malignancy. The observed HPV infection rate indicated the presence of high-risk HPV in the studied population, and the results are consistent with findings from other regional studies. These results underscore the importance of early detection of HPV infection and cervical abnormalities to enable timely clinical intervention and reduce the risk of progression to premalignant or malignant lesions.
References
Abd El All, H. S., Refaat, A., & Dandash, K. (2007). Prevalence of cervical neoplastic lesions and human papillomavirus infection in Egypt: National cervical cancer screening project. Infectious Agents and Cancer, 2(1), 1–14. https://doi.org/10.1186/1750-9378-2-12
Arbyn, M., Weiderpass, E., Bruni, L., de Sanjosé, S., Saraiya, M., Ferlay, J., & Bray, F. (2020). Estimates of incidence and mortality of cervical cancer in 2018: A worldwide analysis. The Lancet Global Health, 8(2), e191–e203. https://doi.org/10.1016/S2214-109X(19)30482-6
Cardoza-Favarato, L. L., & Gastezzi-Arias, M. G. (2023). Human papillomavirus. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK448132/
Factores de riesgo y prevención del cáncer: casos nuevos en 2022. (s. f.).
Castellsagué, X., et al. (2007). Vaccine, 25S, C1–C26.
Muñoz, N., Méndez, F., Posso, H., Molano, M., Van den Brule, A. J. C., Ronderos, M., Meijer, C., & Muñoz, Á. (2004). Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. Journal of Infectious Diseases, 190(12), 2077–2087. https://doi.org/10.1086/425907
QIAGEN. (2020). Test kit definitions (pp. 1–62). https://doi.org/10.32388/jky7dt
Morbidity and Mortality Weekly Report. (2018). Trends in human papillomavirus-associated cancers — United States, 1999–2015, 2–9.
Ministerio de Salud. (2022). Lineamientos técnicos para la prevención y control del cáncer cérvico uterino y de mama (1.ª ed., pp. 10–127). https://www.paho.org/els/index.php?option=com_docman&view=download&alias=1747-lineamientos-prevencion-cancer-cervico-uterino-y-de-mama-7&Itemid=292
Sanabria, J. G., Fernández, Z., Cruz, I., Pérez, L., & Llanuch, M. (2011). El cáncer cervicouterino y las lesiones precursoras: revisión bibliográfica. Revista de Ciencias Médicas, 15(4), 295–319.
Sankaranarayanan, R., Budukh, A. M., & Rajkumar, R. (2001). Effective screening programmes for cervical cancer in low- and middle-income developing countries. Bulletin of the World Health Organization, 79(10), 954–962.
Strander, B., Andersson-Ellström, A., Milsom, I., & Sparén, P. (2007). Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: Population based cohort study. British Medical Journal, 335(7629), 1077–1080. https://doi.org/10.1136/bmj.39363.471806.BE
Garland, S. M., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Harper, D. M., Leodolter, S., Tang, G. W. K., Ferris, D. G., Steben, M., Bryan, J., Taddeo, F. J., Railkar, R., Esser, M. T., Sings, H. L., Nelson, M., Boslego, J., Barr, E., & Koutsky, L. A. (2007). Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. The New England Journal of Medicine, 356(19), 1928–1943. https://doi.org/10.1056/NEJMoa061760
Vargas Hernández, V. M., & Becerril, C. (2018). Virus del papiloma humano. Editorial Alfil.
Williams, J., Kostiuk, M., & Biron, V. L. (2022). Molecular detection methods in HPV-related cancers. Frontiers in Oncology, 12, 1–16. https://doi.org/10.3389/fonc.2022.864820
Yang, X., Huang, L., Li, C., Ji, N., & Zhu, H. (2022). The effectiveness of mindfulness-based stress reduction intervention on alleviating anxiety and depression in postoperative patients with cervical cancer: A protocol for systematic review and meta-analysis. Medicine, 101(5), Article e28706. https://doi.org/10.1097/MD.0000000000028706
Ying, H., Jing, F., Fanghui, Z., Youlin, Q., & Yali, H. (2014). High-risk HPV nucleic acid detection kit—the careHPV test: A new detection method for screening. Scientific Reports, 4, 1–5. https://doi.org/10.1038/srep04704
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2026 Authors who publish in Revista Minerva agree to the following terms: Authors continue as owners of their work, assigning only dissemination rights to Minerva Magazine under the standards of the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows others to mix, adapt and build upon the work for any purpose, including commercially, and although new works must also acknowledge the initial author, they do not have to license derivative works under the same terms.